Matsuno et al. [34] demonstrated in their studies on mice that VEGF plays an important role in the pathogenesis of depression by increasing blood–brain barrier permeability, suggesting that VEGF-A receptor inhibition could be a potential treatment strategy. Here, VEGFA is linked to depressive symptom measurement.